[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Controversies in Neurology
March 2000

Levodopa Toxicity in Parkinson Disease: Reality or Myth?Reality—Practice Patterns Should Change

Author Affiliations

From the Department of Neurology, University of Miami School of Medicine, Miami, Fla.

 

VLADIMIRHACHINSKIMD, DSc

Arch Neurol. 2000;57(3):406-408. doi:10.1001/archneur.57.3.406

THERE IS ample evidence to warrant a change of our clinical practice with regard to levodopa therapy in patients with Parkinson disease (PD), although considerable confusion has clouded the issue of the rationale underlying this change. Concerns regarding "levodopa toxicity" initially emanated from a number of basic science reports suggesting that levodopa has the potential to hasten injury and death of the nigral neuron. However, over time, the distinction between in vitro data and clinical observation blurred, and both clinicians and patients began to erroneously merge the pressing problems of clinical management in advanced PD (eg, motor fluctuations, dyskinesia) with the concept of levodopa toxicity. The need for an accurate definition of levodopa toxicity lies at the heart of this issue.

First Page Preview View Large
First page PDF preview
First page PDF preview
×